Medical Dialogues

MSN Lab gets CDSCO panel nod for Phase IV CT of Tofacitinib Tablets 10 mg

The Subject Expert Committee (SEC) functioning under the Central Drugs Standard Control Organisation (CDSCO) has granted approval to MSN Laboratories to conduct a Phase IV clinical ...
CIDRAP

Trial: Paxlovid retreatment after COVID rebound tied to faster drop in viral RNA but no clinical benefit

Symptomatic or viral rebound is estimated to occur in 0.8% to 32% of Paxlovid recipients and 1.1% to 31% of those who receive ...
Self Employed on MSN

Researchers Map AI’s Impact On Accountants

The post Researchers Map AI’s Impact On Accountants appeared first on Self Employed.
The Malaysian Reserve

FDA Approves Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination as First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

Combination reduced the risk of disease progression or death by 46% and risk of death by 27% in pivotal Phase 3 IMforte trial Zepzelca and atezolizumab ...